Online inquiry

IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5365MR)

This product GTTS-WQ5365MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets env gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Pseudomonas aeruginosa; Homo sapiens
RefSeq NP_579894.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 155971
UniProt ID P04578
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5365MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1232MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ8192MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ1660MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ3198MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ69MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ10180MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ15720MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ1878MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW